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Abstract
Background: Insulin-like growth factor binding protein (IGFBP)-3 functions as a carrier of insulin-
like growth factors (IGFs) in circulation and a mediator of the growth suppression signal in cells.
There are two reported p53 regulatory regions in the IGFBP3 gene; one upstream of the promoter
and one intronic. We previously reported a hot spot of promoter hypermethylation of IGFBP-3 in
human hepatocellular carcinomas and derivative cell lines. As the hot spot locates at the putative
upstream p53 consensus sequences, these p53 consensus sequences are really functional is a
question to be answered.
Methods: In this study, we examined the p53 consensus sequences upstream of the IGFBP-3
promoter for the p53 induced expression of IGFBP-3. Deletion, mutagenesis, and methylation
constructs of IGFBP-3 promoter were assessed in the human hepatoblastoma cell line HepG2 for
promoter activity.
Results: Deletions and mutations of these sequences completely abolished the expression of
IGFBP-3 in the presence of p53 overexpression. In vitro methylation of these p53 consensus
sequences also suppressed IGFBP-3 expression. In contrast, the expression of IGFBP-3 was not
affected in the absence of p53 overexpression. Further, we observed by electrophoresis mobility
shift assay that p53 binding to the promoter region was diminished when methylated.
Conclusion:  From these observations, we conclude that four out of eleven p53 consensus
sequences upstream of the IGFBP-3 promoter are essential for the p53 induced expression of
IGFBP-3, and hypermethylation of these sequences selectively suppresses p53 induced IGFBP-3
expression in HepG2 cells.
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Background
Insulin-like growth factor binding protein (IGFBP)-3 is a
multifunctional protein ferrying insulin-like growth fac-
tors (IGFs) in circulation and mediating growth suppres-
sion signals in cells. Serum IGFBP-3 protein (< 5000 ng/
ml) complexes with IGFs and an acid labile subunit (ALS),
to extend the half lives and modulate the bio-availability
of IGFs [1]. While a precise mechanism of action is not
clear, the growth suppressive activity of IGFBP-3 depends
on its nuclear translocation [2]. Other growth suppressors
such as p53, retinoic acids, transforming growth factor
(TGF)-β, and tumor necrosis factor (TNF)-α induce
IGFBP-3 as a mediator of growth suppression [3-6]. The
growth suppression by IGFBP-3 is independent from the
modulation of IGFs action [7-9]. The functional impor-
tance of the IGFBP-3 in the growth suppression is
noteworthy.
IGFBP-3 is produced in most tissues, but the main site of
production is liver. It is produced by non-parenchymal
cells (endothelial and Kupffer cells) while parenchymal
cells (hepatocytes) do not produce it under normal condi-
tion [10]. We postulate that IGFBP-3 is a gene induced by
growth suppression signals such as p53 in hepatocytes.
While the growth suppression imported by IGFBP-3 sug-
gests the potential for tumor suppression, polymor-
phisms, but no significant mutations were observed in a
survey of several tumors [11]. As gene silencing may occur
without mutations, we recently investigated IGFBP-3 pro-
moter hypermethylation in human hepatocellular carci-
noma [12]. These promoter hypermethylations were
subsequently reported in other tumors systems [13,14].
Promoter analysis of IGFBP-3 indicated that the NaB-RE
sequence is essential for the sodium butyrate (NaB)
induced IGFBP-3 expression [15], but the importance of
the eleven upstream p53 binding sites reported by Bour-
don et al. were not confirmed until now [16]. The methyl-
ation hot spot we identified exactly matched the putative
p53 binding sites that Bourdon et al. indicated. Thus, we
postulated that these sites are important for the expression
of IGFBP-3 induced by p53. Moreover, we hypothesized
that the suppression of apoptosis mediated by IGFBP-3
due to the promoter hypermethylation will be a possible
pathway of hepatocarcinogenesis. To explore this possi-
bility, the functions of the promoter upstream binding
sites of p53 were examined precisely in this study.
Methods
Cell culture
HepG2 cells were obtained from Japanese Cancer
Research Resources Bank (Tokyo, Japan), and maintained
in D-MEM supplemented with 10 % FCS (Life Technolo-
gies, Tokyo, Japan), antibiotic-antimycotics at 37°C in a
humidified atmosphere of 95 % air and 5 % CO2.
Plasmids
pGL2-IGFBP-3, kindly provided by Dr. Youngman Oh
(Oregon Health Sciences University, Portland, OR), car-
ries a 1.9 kb IGFBP-3 promoter (-1805/+69) in pGL2-
Basic (Promega Corp., Madison, WI). A series of deletion
mutant constructs, pGL2-270, pGL2-240, pGL2-210,
pGL2-180, pGL2-150, pGL2-120, pGL2-90, pGL2-60,
pGL2-30, and pGL2-1 containing the indicated fragments
upstream of the transcription start site and 60 bp of frag-
ments downstream of the transcription start site, were
generated by PCR amplification of the promoter fragment
and subsequent subcloning of the Mlu I-Bgl II fragment to
pGL2-Basic (Table 1, Fig. 2). The transcription start site of
Table 1: Oligonucleotide DNAs used for construction of IGFBP-3 promoter mutants.
Plasmid Cloned fragment* sense primer** (5' to 3') antisense primer** (5' to 3')
pGL2-270 -270/+60 ggacgcgtctggagtgccggggtggc ggagatctgctgtggaatccaggcag
pGL2-240 -240/+60 ggacgcgtggttcttgtagacgacaa ggagatctgctgtggaatccaggcag
pGL2-210 -210/+60 ggacgcgtcgggcgtgagcacgagga ggagatctgctgtggaatccaggcag
pGL2-180 -180/+60 ggacgcgtgcgagtctcgagctgcac ggagatctgctgtggaatccaggcag
pGL2-150 -150/+60 ggacgcgtggccccggctgctcaggg ggagatctgctgtggaatccaggcag
pGL2-120 -120/+60 ggacgcgtcccgcagccgtgcctgcg ggagatctgctgtggaatccaggcag
pGL2-90 -90/+60 ggacgcgtcctcccaacccccactcc ggagatctgctgtggaatccaggcag
pGL2-60 -60/+60 ggacgcgtccggggcgtgtcctgggc ggagatctgctgtggaatccaggcag
pGL2-30 -30/+60 ggacgcgttatatacgggccggcgcg ggagatctgctgtggaatccaggcag
pGL2-1 +1/+60 ggacgcgtagatgcgagcactgcggc ggagatctgctgtggaatccaggcag
pGL2-210B*** -210/+60 ggacgcgtctgcagcgggcgtgagcacga
ggagcaggtgcccgggtgactctcgagct
agctcgagagtcacccgggcacctgctcc
tcgtgctcacgcccgctgcagacgcgtcc
*; The number is indicated by transcription start site as +1.
**; Mlu I restriction site is included in sense primers and Bgl II restriction site is included in antisense primers.
***; pGL-210B was made by replacing Mlu I-Xho I fragment of pGL2-210 with the oligonucleotide DNA indicated.BMC Cancer 2005, 5:9 http://www.biomedcentral.com/1471-2407/5/9
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the IGFBP-3 promoter, +1, is based on the sequence deter-
mined by Cubbage et al. [17]. The plasmid containing
site-directed mutations in putative p53 binding sites was
generated by replacing the wild type Mlu I-Xho I fragment
of pGL2-210 with a mutant fragment synthesized artifi-
cially (pGL2-210B, Table 1, Fig. 3). A fusion gene with
site-directed methylation was constructed by methylating
the Mlu I-Xho I fragment (-210/-174) of pGL2-210 in vitro
with Sss I methylase (New England Biolabs, Inc., Beverly,
MA), and reconstituting the fragment and unmethylated
vector (Fig. 4). pCMV-p53 and pCMV-p53mt135 were
obtained from BD-Biosciences (East Meadow Circle, Palo
Alto, CA).
Transient transfection
HepG2 cells were transiently transfected using the
FuGENE 6 transfection reagent according to the manufac-
turer's instructions (Roche Molecular Biochemicals, Indi-
anapolis IN). Cells were seeded at a density of 5 × 104
cells/well in 24-well plates. After 24 hours, cells were
transfected with 0.25 µg/well of reporter plasmid DNA in
serum-containing medium. Forty-eight hours post trans-
fection, cells were washed twice with PBS and collected for
luciferase assays. Transfections were performed in quadru-
plicate and experiments were performed at least two
times.
Luciferase assay
Luciferase activities of cell lysates were measured accord-
ing to the manufacturer's instructions (Promega Corp.
Madison, WI) using a liquid scintillation counter (Aloka,
LSC-700, Tokyo, Japan). Luciferase activities were normal-
ized for total protein determined using the Bradford Assay
(Bio-Rad Laboratories, In., Hercules, CA).
EMSA (electrophoresis mobility shift assay)
278 bp of the Mlu  I-Bgl  II fragment of pGL-210 were
labelled using [α-32P]dCTP by end filling with Klenow
fragment, and used for EMSA. Oligonucleotide DNAs
(BP3WPSF: 5'-GGCTGCAGCG GGCGTGCGCA CGAG-
GAGCAG GTGCCCGGGC GAGTCTCGAG
CTGCACGCCC CCGAGCTCGG-3', BP3WPSR: 5'-
CCGAGCTCGG GGGCGTGCAG CTCGAGACTC
GCCCGGGCAC CTGCTCCTCG TGCGCACGCC CGCT-
GCAGCC-3'), comprising the promoter sequence of -210/
-149, were custom-made (Sigma-genosys Japan, Ishikari,
Japan), annealed one hour at room temperature, and used
as cold competitor in the assay. EMSA was performed in a
Schematic genomic structure of the IGFBP3 gene Figure 1
Schematic genomic structure of the IGFBP3 gene. There exist 11 p53 consensus sequences upstream of the promoter 
[16] and two binding sites in introns [3]. Polymorphisms and hypermethylations are identified in the promoter upstream p53 
binding sites [26, 12].
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20 µl reaction containing 10 mM Tris (pH 7.5), 2.5%
Glycerol, 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, and in
the presence of 50 ng/µl of double-stranded poly [d(I-C)],
5000 cpm (2 ng) of 32P-labeled probe DNA, and 2.5 µg of
H2O2 treated MCF7 nuclear extract (Active motif LLC, Pal-
omar, CA). The reaction mixture was incubated at 14°C
for 20 min. 20 µl of each reaction mixture was then
loaded onto a native 4 % polyacrylamide gel containing
0.5 × Tris-Glycine buffer (25 mM Tris, 190 mM Glycine, 1
mM EDTA pH 8.3), and electrophoresed at 14°C, 100 V
for 1 hr. For the supershift assay, a p53 antibody (Ab-2,
Oncogene Research Products, San Diego, CA) was used.
Results
Deletion analysis
We identified a hot spot of promoter hypermethylation in
human hepatocellular carcinoma and its cell lines in the
promoter upstream region of IGFBP-3 (Fig. 1). As methyl-
ation sites were identified to the cluster of putative p53
binding sites, we examined the role of these sites in
IGFBP-3 expression. First, we constructed promoter dele-
tion mutants of IGFBP-3 and examined the expression of
the reporter gene in the absence (Fig. 2A) and presence
(Fig. 2B) of p53 expression by the co-transfection of a p53
expression plasmid (pCMV-p53). As the transfection effi-
Deletion analysis of IGFBP-3 promoter for the induction by p53 Figure 2
Deletion analysis of IGFBP-3 promoter for the induction by p53. HepG2 cells were transiently transfected with the 
panel of IGFBP-3 promoter-luciferase reporter constructs with (B) or without (A) co-transfection by pCMV-p53, and luciferase 
activity was measured after 48 h. Mean count of luciferase activity +/- SEM is shown.
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Mutant analysis of IGFBP-3 promoter for the induction by p53 Figure 3
Mutant analysis of IGFBP-3 promoter for the induction by p53. A, Schematic of four wild type p53 consensus 
sequence of IGFBP-3 (-159/-209) of pGL2-210 and mutant sequence carrying point mutations in the core consensus sequence 
(-179 C to T, -176 G to C) of pGL2-210B. B, HepG2 cells were transiently transfected with wild type IGFBP-3 promoter-luci-
ferase reporter constructs pGL2-210 or mutant IGFBP-3 promoter-luciferase reporter constructs pGL2-210B with (filled box) 
or without (open box) co-transfection by pCMV-p53, and luciferase activity was measured after 48 h. Mean count of luciferase 
activity +/- SEM is shown.
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Methylation analysis of IGFBP-3 promoter for induction by p53 Figure 4
Methylation analysis of IGFBP-3 promoter for induction by p53. A, Schematic of four wild type p53 consensus 
sequence of IGFBP-3 (-159/-209) of pGL2-210 and a sequence of the methylated construct carrying the CpG methylation in 
the core consensus sequence (underlined) of pGL2-210. B, HepG2 cells were transiently transfected with wild type IGFBP-3 
promoter-luciferase reporter construct or methylated IGFBP-3 promoter-luciferase reporter construct with (filled box) or 
without (open box) co-transfection by pCMV-p53, and luciferase activity was measured after 48 h. Mean count of luciferase 
activity +/- SEM is shown.
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ciency was not fully controlled, and p53 overexpression
may to cause massive changes in cellular conditions, we
did not compare results between the presence and
absence of p53. Even though, we can obtain clear results
about the effect of p53 to IGFBP-3 expression. The pattern
of expression of deletion mutants was clearly different in
the absence and presence of p53. In the absence of p53
overexpression, we identified the NaB-RE sequence as an
essential site for expression, and deletion of p53 binding
site enhanced the gene expression (Fig. 2A). These obser-
vations were similar to those of Walker et al. [15], but dif-
fered as HepG2 cell does not require NaB or Tricostatin A
(TSA) for its activation. In contrast, in the presence of p53
over-expression, we identified that four p53 binding sites
between -210 to -150 (relative transcription start site as
+1) were essential for IGFBP-3 expression (Fig. 2B). When
the deletion constructs were co-transfected with pCMV-
p53mt135, the expression of the IGFBP-3 promoter was
suppressed to a background level (almost same as blank
constructs) in all constructs (data not shown). This
indicates that IGFBP-3 expression we observe is tightly
regulated by p53.
Site-directed mutagenesis
To confirm the importance of p53 binding sites between -
210 to -150, we abrogated one of p53 binding sites by site-
directed mutagenesis (C to T at -179 and G to C at -176,
Fig. 3A). In the absence of p53 overexpression, there exist
little differences in expression between the wild type and
mutant construct (74 % relative to the wild type) (Fig.
3B). However, in the presence of p53 overexpression,
IGFBP-3 expression was strongly decreased in the mutant
construct (3.4 %) relative to wild type (Fig. 3B). For rea-
sons already mentioned, we did not compare the result
between in presence and absence of p53.
Site-directed methylation
Next, we constructed in vitro methylated promoter con-
structs to evaluate the effect of methylation (Fig. 4A). For
methylation, the Mlu I-Xho I fragment of pGL2-210 was
methylated with Sss I methylase and reconstituted with
unmethylated reporter vector fragment. As we used linear
constructs for the transfection, the expression of luciferase
was strongly suppressed compared to circular plasmids
(0.7 %). But similar patterns compared to site directed
mutation were observed. Although the expression of
IGFBP-3 was slightly enhanced in the absence of p53 over-
expression in the methylated construct, it was decreased
in the presence of p53 overexpression in the methylated
construct (Fig. 4B). In this experiment, at a glance, we
observed induction of IGFBP-3 expression by p53, but the
transfection efficiency of linear plasmids is low, while the
relative levels of p53 and the availability of putative nega-
tive regulators are extremely different from other experi-
ments. Thus, we cannot conclude in this case, whether or
not there is induction by p53.
EMSA
EMSA was performed to determine whether p53 protein
binding was disturbed by methylation. In this assay, the
wild type and methylated promoter fragments (278 bp, -
210/+60) were incubated with H2O2-treated MCF7
nuclear extract that express high level of p53. In the wild
type promoter probe, we observed supershifted complex
(Fig. 5, lane 4, indicated by arrows) when p53 antibody
(Ab-2) is added to the reaction mixture. A 100-fold molar
excess of a cold 70 bp sequence containing a p53 binding
site (-210/-149), competed the probe (Fig. 5, lane 5). In
methylated probe, we observed no supershifted complex
(Fig. 5, lane 9). As we used probes that contain a Sp1/GC
box and TATA box, we observed the shift and supershift
bands in the methylated probe as well as unmethylated
probe. These bands were postulated to be due to p53
binding to the nuclear factor such as p300. These observa-
tions indicate that p53 binding to the IGFBP3 promoter
sequence is blocked or at least attenuated by
hypermethylation.
Discussion
We have indicated that the p53 binding sites upstream of
IGFBP-3 promoter are essential for its induction by p53,
and that the induction can be suppressed by promoter
hypermethylation in the human hepatoblastoma cell line
HepG2. A working model of the p53 action in IGFBP-3
promoter upstream binding sites is summarized in Fig. 6.
In this model, in normal cells, IGFBP-3 is induced by fac-
tors such as growth hormone (GH) and IGFs, and steady
levels of expression are observed in some cells. That the
deletion of p53 binding sites enhances the expression of
IGFBP-3, suggests existence of negative regulators (Fig.
6A). In apoptotic cells, p53 tetramers at high levels of
expression bind to upstream binding sites. These
tetramers recruit the p300 complex to its binding site,
thereby a p53-dependent high level of expression (Fig.
6B). In tumor cells, deletions, mutations, methylations of
p53 binding sites, or mutations of p53 such as p53mt135,
disturb the binding of p53 tetramers to their binding sites,
and this prevents the binding of the p300 complex to
IGFBP-3 promoter. As a result, the expression of IGFBP-3
is suppressed in tumor cells (Fig.6C). In this model, pro-
moter hypermethylation has the same effect as promoter
mutation in determining IGFBP-3 expression.
Our observations of promoter hypermethylation in
human hepatocellular carcinomas and derivative cell
lines (12), and the observations in this report strongly
support the notion that IGFBP3 is a true tumor suppressor
gene. IGFBP3 is a gene that is silenced by biallelic hyper-
methylation or hypermethylation and loss of heterogene-BMC Cancer 2005, 5:9 http://www.biomedcentral.com/1471-2407/5/9
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Specific binding of p53 to IGFBP-3 promoter and its inhibition by methylation Figure 5
Specific binding of p53 to IGFBP-3 promoter and its inhibition by methylation. 2 ng of end-labelled 278 bp of Mlu I-
Bgl II fragment of pGL-210 were used for EMSA. To construct the methylated probe, a labelled fragment was methylated in vitro 
with Sss I methylase. Each reaction contained the components listed in Materials and Methods. 2.5 µg of H2O2-treated MCF7 
with an induced p53 expression was used as nuclear extract. Supershift was obtained using 0.1 µg of anti-p53 (Ab-2). As com-
petitor, 200 ng of the fragment that carries the core p53 binding site (-210/-149) were used. The mixture was incubated at 
room temperature for 20 min and analyzed on 4 % nondenaturating polyacrylamide gel in 0.5 × Tris-Glycine buffer. Supershift 
bands observed in lane 4 were indicated by arrows.BMC Cancer 2005, 5:9 http://www.biomedcentral.com/1471-2407/5/9
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ity (LOH) in human hepatocellular carcinoma. As
reported recently [14], we have also observed the reduced
expression of IGFBP-3 in several tumors such as, breast (9/
41), uterus (11/42), ovary (6/16), kidney (6/20), and
prostate (1/4) using the cancer profiling array (BD bio-
science, data not shown). We therefore postulate that the
tumor suppressor role of IGFBP-3 will not be limited to
HCCs. In addition, there are also many reports of IGFBP-
3 overexpression in tumors from breast [18], prostate
[19], kidneys [20], and lung squamous cells [21], so on.
We thus anticipate the existence of additional defects,
such as papilloma virus infections that inactivate IGFBP-3
[22], TGF-β / Rb signalling abnormalities that often coin-
cide with IGFBP-3 overexpression [23-25], or as yet
unknown defects in IGFBP-3 receptor function leading to
IGFBP-3, for these overexpression in tumors.
IGFBP-3 is a ubiquitous, multifunctional protein, whose
importance as a carrier of IGFs is evident. The absence of
gross loss-of-function mutations of IGFBP-3 observed to
date likely underscores its functional importance. We
hypothesize that IGFBP-3 is a gene whose basal level of
Working model of p53 action to IGFBP-3 promoter Figure 6
Working model of p53 action to IGFBP-3 promoter. In normal cells, IGFBP-3 is induced by such as growth hormone 
and IGFs, and steady level of expression is observed in some cells. As the deletion of p53 binding sites enhances the expression 
of IGFBP-3, the binding of negative regulators is expected (Fig. 6A). In apoptotic cells, p53 tetramers at high level of expression 
bind to upstream binding sites. These tetramers recruit the p300 complex to its binding site, and a p53 dependent high level of 
expression is observed (Fig. 6B). In tumor cells, deletions, mutations, methylations of p53 binding sites, or mutations of p53 
such as p53mt135, disturb the binding of p53 tetramers to its binding sites, and this prevents the binding of p300. As a result, 
the expression of IGFBP-3 is suppressed in tumor cells.
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expression is essential for cell survival, but upon induc-
tion by p53, high levels of expression of IGFBP-3 induces
apoptosis. Alternatively, IGFBP-3 may be a gene that is
essential for cell survival when induced by growth hor-
mones or IGFs, but functions as an apoptotic mediator
when induced by p53.
We observed slight base changes within p53 binding sites
strongly influenced the induction of IGFBP-3 by p53. As
SNPs that change the expression level of IGFBP-3 were
within p53 binding sites [26], and it was reported that the
IGFBP-3 is differentially activated by p53 mutants
[27,28], we postulate that the expression and functions of
IGFBP-3 is controlled in some way by p53 binding sites in
the promoter of IGFBP-3. This may include the intronic
p53 binding sites as well as the upstream sites explored
here. IGFBP-3 may, therefore, have an important function
in tumor development through p53 control.
We identified the MyoD (-195/-186) and WT1 (-164/-
156) binding sites as well as p53 binding sites at the
hypermethylation hot spot in HCC by promoter analysis
using TRANSFAC (v 4.0). As MyoD is a transcription fac-
tor that can induce apoptosis, and WT1 is a tumor sup-
pressor gene, the existence of a binding site for these
putative regulator genes in the hot spot of the promoter of
IGFBP-3 suggest the possibility that these genes also use
IGFBP-3 as a mediator of their actions.
Conclusions
We conclude that four out of eleven p53 consensus
sequences upstream of the IGFBP-3 promoter are essential
for the p53 induced expression of IGFBP-3, and hyper-
methylation of these sequences selectively suppresses p53
induced IGFBP-3 expression in HepG2 cells. As IGFBP-3
functions downstream of many growth suppressors and
its growth suppression effects are drastic, and as it is a
small-sized secreted protein, the use of IGFBP-3 in tumor
therapy will be a promising option.
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